Diabetes Oral Medications/Anti-Diabetic Medications

Drugs used in diabetes treat diabetes mellitus by lowering glucose levels in the blood. With the exceptions of Insulin, exenatide, liraglutide and pramlintide, all are administered orally and are thus also called oral hypoglycemic agents or oral antihyperglycemic agents. There are different classes of anti-diabetic drugs, and their selection depends on the nature of the diabetes, age and situation of the person, as well as other factors.
Diabetes mellitus type 1 is a disease caused by the lack of insulin. Insulin must be used in Type I, which must be injected.
Diabetes mellitus type 2 is a disease of insulin resistance by cells. Type 2 diabetes mellitus is the most common type of diabetes. Treatments include (1) agents that increase the amount of insulin secreted by the pancreas, (2) agents that increase the sensitivity of target organs to insulin, and (3) agents that decrease the rate at which glucose is absorbed from the gastrointestinal tract.
Several groups of drugs, mostly given by mouth, are effective in Type II, often in combination. Insulin sensitizers address the core problem in Type II diabetes—insulin resistance.
Thiazolidinediones (TZDs), also known as "glitazones," bind to PPARγ, a type of nuclear regulatory protein involved in transcription of genes regulating glucose and fat metabolism.
Secretagogues are drugs that increase insulin output from the pancreas. Meglitinides help the pancreas produce insulin and are often called "short-acting secretagogues".
Alpha-glucosidase inhibitors are "diabetes pills" but not technically hypoglycemic agents because they do not have a direct effect on insulin secretion or sensitivity. Dipeptidyl peptidase-4 (DPP-4) inhibitors increase blood concentration of the incretin GLP-1 by inhibiting its degradation by dipeptidyl peptidase-4.

  • Meglitinides – nateglinide (Nonsulfonylurea secretagogues)
  • Biguanides – metformin (Insulin Sensitizers)
  • Sulfonylureas - glimepiride, glipizide, glyburide ( Secretagogues)
  • Thiazolidinediones (Tzd) – pioglitazone (Insulin Sensitizers)
  • Alpha-glucosidase inhibitors – Acarbose (Diabetes Pills)
  • Injectable Incretin mimetics
  • Injectable Amylin analogues
  • Glycosurics (sodium/glucose cotransporter 2 (SGLT2)Inhibitors)

Related Conference of Diabetes Oral Medications/Anti-Diabetic Medications

November 21-22, 2018

14th World Congress on Endocrinology & Diabetes

Paris, France
November 26-27, 2018

26th International Diabetes and Healthcare Conference

Helsinki, Finland
November 26-27, 2018

13th European Diabetes and Endocrinology Congress

Dublin, Ireland
February 27-28, 2019

Asia Pacific Diabetes and Endocrinology Congress

Tokyo, Japan

April 17-18, 2019

21st Asia Pacific Diabetes Conference

Osaka,Japan
April 29-30, 2019

2nd Global Meeting on Diabetes and Endocrinology

Istanbul, Turkey
June 10-11, 2019

28th European Diabetes Congress

| Edinburgh, Scotland
July 24-25, 2019

29th World Diabetes & Heart Congress

Melbourne, Australia
July 29-30, 2019

12th International Conference on Diabetes & Metabolism

Chicago | Illinois| USA
Oct 03-04, 2019

Euro Diabetes Congress & Expo

| Paris, France

Diabetes Oral Medications/Anti-Diabetic Medications Conference Speakers

Recommended Sessions

Related Journals

Are you interested in